PuSH - Publikationsserver des Helmholtz Zentrums München: Cancer Progression and Tumor Cell Motility Are Associated with the FGFR4 Arg388 Allele.

Informationen

Hinweise zu Qualitätskriterien von Zeitschriften

Open-Access-Richtlinie der Helmholtz-Gemeinschaft 2016

CC Licencences

Metriken für Publikationen

Navigation

Startseite

English

EVA: Veröffentlichen

Neuer EVA Antrag

Recherche

Erweiterte Suche

Durchblättern nach ...

... HMGU-Autoren/Konsortien

... Organisationsstruktur

... Zeitschriften

... Publikationstypen

... Forschungsdaten

... Arbeitsgruppen

... Erscheinungsjahr

Publikationen im Überblick

Statistik

HGF Fortschrittsbericht

OA Publikationen

Eintragen

Neue Publikation eintragen

Neue Publikation holen aus...

...EVA

Fehlende Publikation melden

Highlights

Suche

Hilfe & Kontakt

Ansprechpartner

Hilfe

Datenschutz

Helmholtz Open Science

Bibliometrische Indikatoren

SHERPA/RoMEO

DOAJ

Export:

Text

Endnote (RIS) BIB

BibTeX

Bange, J.* ; Prechtl, D.* ; Cheburkin, Y.* ; Specht, K. ; Harbeck, N.* ; Schmitt, M.* ; Knyazeva, T.* ; Müller, S.* ; Gärtner, S.* ; Sures, I.* ; Wang, H.* ; Imyanitov, E.* ; Häring, H.-U.* ; Knayzev, P.* ; Iacobelli, S.* ; Höfler, H. ; Ullrich, A.*

Cancer Progression and Tumor Cell Motility Are Associated with the FGFR4 Arg388 Allele.

Cancer Res. 62, 840-847 (2002)

Verlagsversion

DOI

	Closed

Open Access Green möglich sobald Postprint bei der ZB eingereicht worden ist.

Abstract
Metriken
Zusatzinfos

Expression analysis of genes encoding components of the phosphotyrosine signaling system by cDNA array hybridization revealed elevated levels of FGFR4 transcripts in several mammary carcinoma cell lines. In the FGFR4 gene transcript from MDA-MB-453 mammary carcinoma cells, a G to A conversion was discovered that results in the substitution of glycine by arginine at position 388 in the transmembrane domain of the receptor. The Arg³⁸⁸ allele was also found in cell lines derived from a variety of other tumor types as well as in the germ-line of cancer patients and healthy individuals. Analysis of three geographically separated groups indicated that it occurs in approximately 50% of the human population. Investigation of the clinical data of 84 breast cancer patients revealed that homo- or heterozygous carriers of the Arg³⁸⁸ allele had a significantly reduced disease-free survival time (P = 0.01) within a median follow-up of 62 months. Moreover, the FGFR4 Arg³⁸⁸ allele was associated with early lymph node metastasis and advanced tumor-node-metastasis (TNM) stage in 82 colon cancer patients. Consistent with this finding, MDA-MB-231 mammary tumor cells expressing FGFR4 Arg³⁸⁸ exhibited increased motility relative to cells expressing the FGFR4 Gly³⁸⁸ isotype. Our results support the conclusion that the FGFR4 Arg³⁸⁸ allele represents a determinant that is innocuous in healthy individuals but predisposes cancer patients for significantly accelerated disease progression.

Impact Factor

Scopus SNIP

Altmetric

8.302

0.000